Mitochondrial bioenergetic signatures differentiate asymptomatic from symptomatic Alzheimer’s disease
11 affiliations
- 1PULSe Integrative Neuroscience program, Purdue University, West Lafayette, IN, USA
- 2Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA
- 3School of Health Sciences, Purdue University, West Lafayette, IN, USA
- 4Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA
- 5Department of Neurology, Mayo Clinic, Rochester, MN, USA
- 6Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
- 7Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
- 8Department of Medicine, Duke University, Durham, NC, USA
- 9Duke Institute of Brain Sciences, Duke University, Durham, NC, USA
- 10Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN, USA. [email protected]
- 11School of Health Sciences, Purdue University, West Lafayette, IN, USA. [email protected]
Abstract
Asymptomatic Alzheimer's disease (AsymAD) refers to individuals who, despite exhibiting amyloid-β plaques and tau pathology comparable to Alzheimer's disease (AD), maintain cognitive performance similar to cognitively normal individuals. The resilience mechanism in AsymAD individuals remains understudied. We performed a systematic analysis comparing AsymAD and AD across multiple cohorts (ROSMAP, Banner and Mount Sinai), brain regions (BA6, BA9, BA36 and BA37) and neuronal and glial cell types using proteomics and transcriptomics data. AsymAD brains exhibited preserved mitochondrial bioenergetics, characterized by enhanced oxidative phosphorylation, electron transport chain activity, fatty acid and lipid metabolism, and branched-chain amino acid utilization. Pathways regulating mitochondrial complex biogenesis and calcium homeostasis were also upregulated. Key mitochondrial proteins such as MRPL47, CPT2, BCAT2, and IDH2, were consistently upregulated in AsymAD. At the cellular level, excitatory neurons, including superficial, mid-layer, and deep-layer subtypes, exhibited the most preserved mitochondrial function, whereas vulnerable inhibitory subtypes, including PVALB and SST neurons, showed increased cellular abundance and bioenergetic activity. In contrast, microglia and oligodendrocytes proportions were reduced in AsymAD relative to AD. Our findings identify preserved mitochondrial bioenergetics in AsymAD and suggest that enhancing NADH metabolism via NAD+ precursor-based interventions may potentially help in maintaining cognitive function despite amyloid and tau pathology.
Related
- Mitochondrial and bioenergetic processes are enriched in large-but are reciprocally depleted in small extracellular vesicles
- Tuberculosis incidence among household contacts of individuals with symptomatic and asymptomatic tuberculosis: A historical cohort study in the Western Cape province of South Africa
- High prevalence of Plasmodium ovalewallikeri in co-infections with Plasmodium falciparum in symptomatic than asymptomatic Plasmodium parasite infections in Kisumu, Kenya
- Individualised mapping of living human brain mitochondria by MRI reveals signatures of bioenergetic defects.
- Nitric Oxide Attenuates TGF-β-Induced Myofibroblast Differentiation Through Reversible Mitochondrial Bioenergetic Reprogramming Despite Compensatory Glycolytic Activation
BibTeX
@article{mandal2026mitochondrial,
title = {{Mitochondrial bioenergetic signatures differentiate asymptomatic from symptomatic Alzheimer’s disease}},
author = {Purba Mandal and Eugenia V. Trushina and Matthias Arnold and Rima Kaddurah‐Daouk and Priyanka Baloni},
journal = {Communications Biology},
year = {2026},
month = jun,
doi = {10.1038/s42003-026-10474-8},
url = {https://doi.org/10.1038/s42003-026-10474-8},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Mitochondrial bioenergetic signatures differentiate asymptomatic from symptomatic Alzheimer’s disease
AU - Purba Mandal
AU - Eugenia V. Trushina
AU - Matthias Arnold
AU - Rima Kaddurah‐Daouk
AU - Priyanka Baloni
PY - 2026
DA - 2026/06/10
JO - Communications Biology
DO - 10.1038/s42003-026-10474-8
UR - https://doi.org/10.1038/s42003-026-10474-8
AB - Asymptomatic Alzheimer's disease (AsymAD) refers to individuals who, despite exhibiting amyloid-β plaques and tau pathology comparable to Alzheimer's disease (AD), maintain cognitive performance similar to cognitively normal individuals. The resilience mechanism in AsymAD individuals remains understudied. We performed a systematic analysis comparing AsymAD and AD across multiple cohorts (ROSMAP, Banner and Mount Sinai), brain regions (BA6, BA9, BA36 and BA37) and neuronal and glial cell types using proteomics and transcriptomics data. AsymAD brains exhibited preserved mitochondrial bioenergetics, characterized by enhanced oxidative phosphorylation, electron transport chain activity, fatty acid and lipid metabolism, and branched-chain amino acid utilization. Pathways regulating mitochondrial complex biogenesis and calcium homeostasis were also upregulated. Key mitochondrial proteins such as MRPL47, CPT2, BCAT2, and IDH2, were consistently upregulated in AsymAD. At the cellular level, excitatory neurons, including superficial, mid-layer, and deep-layer subtypes, exhibited the most preserved mitochondrial function, whereas vulnerable inhibitory subtypes, including PVALB and SST neurons, showed increased cellular abundance and bioenergetic activity. In contrast, microglia and oligodendrocytes proportions were reduced in AsymAD relative to AD. Our findings identify preserved mitochondrial bioenergetics in AsymAD and suggest that enhancing NADH metabolism via NAD+ precursor-based interventions may potentially help in maintaining cognitive function despite amyloid and tau pathology.
SN - 2399-3642
ER -